PROCEPT BioRoboticsPRCT +5.77%70 Debt-to-Equity is 0.22 as of Mar. 2026, which is at its 10-year median of 0.22. GuruFocus rates PRCT with a GF Score™ of 70/100 and a GF Value™ of $93.06 (Significantly Undervalued). The stock has 2 warning signs investors should review. Among 704 Medical Devices & Instruments companies, PROCEPT BioRobotics ranks better than 50.85% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for PROCEPT BioRobotics's Debt-to-Equity or its related term are showing as below:
PRCT'
s Debt-to-Equity Range Over the Past 10 Years
Min: -0.3 Med: 0.22 Max: 0.52
Current: 0.22
During the past 7 years, the highest Debt-to-Equity Ratio of PROCEPT BioRobotics was 0.52. The lowest was -0.30. And the median was 0.22.
PRCT's Debt-to-Equity is ranked better than 50.85% of 704
companies
in the Medical Devices & Instruments industry
Industry Median: 0.225
vs PRCT: 0.22
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
PROCEPT BioRobotics Debt-to-Equity Related Terms
PROCEPT BioRobotics Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for PROCEPT BioRobotics's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PRCT vs ENOV, INSP, IRMD: Debt-to-Equity Comparison
For the Medical Devices subindustry, PROCEPT BioRobotics's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
PROCEPT BioRobotics Debt-to-Equity vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, PROCEPT BioRobotics's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where PROCEPT BioRobotics's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PROCEPT BioRobotics (PRCT) has a Debt-to-Equity of 0.22 as of Mar. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on PROCEPT BioRobotics and its competitors. This is near median its historical median of 0.22. According to the industry distribution chart, PROCEPT BioRobotics ranks #346 out of 704 companies in the Medical Devices & Instruments industry, placing it in the top 49.1%.
Is PROCEPT BioRobotics' Debt-to-Equity too high?
PROCEPT BioRobotics' current Debt-to-Equity of 0.22 is near median its 10-year median of 0.22. The Medical Devices & Instruments industry median Debt-to-Equity is 0.23. PROCEPT BioRobotics' value of 0.22 is 2.2% below this industry median. Based on the distribution chart, PROCEPT BioRobotics ranks #346 out of 704 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, PROCEPT BioRobotics has a GF Score™ of 70/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does PROCEPT BioRobotics' Debt-to-Equity compare to ENOV and INSP?
According to the Medical Devices & Instruments industry distribution chart, PROCEPT BioRobotics ranks #346 out of 704 companies for Debt-to-Equity. This puts PROCEPT BioRobotics in the upper half of its industry. The industry median Debt-to-Equity is 0.23. PROCEPT BioRobotics' value of 0.22 is 2.2% below this benchmark. While the company's 10-year median is 0.22 vs. the industry median of 0.23, PROCEPT BioRobotics has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Medical Devices & Instruments company?
The median Debt-to-Equity among Medical Devices & Instruments companies is 0.23, based on 704 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. PROCEPT BioRobotics's current Debt-to-Equity of 0.22 is 2.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on PROCEPT BioRobotics and its competitors. For the Medical Devices & Instruments industry, the median Debt-to-Equity is 0.23 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. PROCEPT BioRobotics's current Debt-to-Equity is 0.22, which is near median its own 10-year median of 0.22. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PROCEPT BioRobotics stock overvalued right now?
Based on GuruFocus' analysis, PROCEPT BioRobotics (PRCT) is currently considered Significantly Undervalued. The stock's GF Value™ is $93.06, compared to a current price of $20.90 — trading 77.5% below its estimated fair value. The current Debt-to-Equity is 0.22, which is near median its 10-year median of 0.22 and 2.2% below the Medical Devices & Instruments industry median of 0.23. PROCEPT BioRobotics' overall GF Score™ is 70/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For PROCEPT BioRobotics (PRCT), the current Debt-to-Equity is 0.22 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is PROCEPT BioRobotics (PRCT) Overvalued in 2026?
Based on GuruFocus' analysis, PROCEPT BioRobotics stock appears to be undervalued.
The current stock price of $20.90 is trading 77.5% below its estimated GF Value™ of $93.06.
GuruFocus considers PROCEPT BioRobotics to be Significantly Undervalued.
Key valuation signals for PRCT:
Debt-to-Equity: 0.22 (near median its 10-year median of 0.22)
GF Value™: $93.06 vs. price of $20.90 (77.5% below fair value)
Industry Position: 2.2% below the Medical Devices & Instruments median (#346 of 704)
No single metric tells the full story. See the PRCT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
PROCEPT BioRobotics Corp is a surgical robotics company focused on advancing patient care by developing transformative solutions in urology. The company develops, manufactures, and sells the AquaBeam Robotic System and HYDROS Robotic System, image-guided, surgical robotic systems for use in minimally invasive urologic surgery, with an initial focus on treating benign prostatic hyperplasia, or BPH. Geographically, the company generates a majority of its revenue from the United States and also has a presence in markets outside the U.S.
70GF Score
Get the complete analysis for PRCT
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PRCT has been successfully added to your 
